1. Home
  2. Lipids, Nanotechnology and Cancer

Lipids, Nanotechnology and Cancer

October 10, 2016 - October 12, 2016
Conference

Hôtel de Ville de Tours
37000 Tours
France

Presentation

Deadline for registration: 06/10/2016 - CLOSED

Disorders in lipid metabolism have now been implicated in the development of many diseases including cancer and cardiovascular diseases. At this stage, the metabolism and function of lipids are poorly understood in part due to the complexities of lipid metabolism regulation. While the role of cholesterol and other lipids has been evident for many years in cardiovascular diseases, their role in cancer development and progression is now beginning to be elucidated. Interestingly, drugs that are used to treat lipid metabolic disorders may show their usefulness for the treatment of cancer. Importantly, new research in drug development suggests that lipid metabolism may be used as a target for the treatment of cancer. This new approach will include the use of biopharmaceuticals and nanotechnologies.

In that regard, the region Centre-Val de Loire funded a research initiative termed the ARD 2020 Biopharmaceuticals programme. One of the research axes focuses on the role of “Lipids as biopharmaceutical response modifiers”. The ARD 2020 research teams are located in laboratories of the University Francois-Rabelais, CNRS, INRA, INSERM, CHRU and University of Orleans. The ARD 2020 programme also involves LE STUDIUM, POLEPHARMA and IMT Group, which are partners engaged in providing support to develop human capital and build pathways to translate the ARD 2020 Biopharmaceuticals research into socio-economic outcomes.

Lipids, nanotechnology and cancer

Main topics of the conference

Biopharmaceuticals, Cellular Lipid Signaling, Lipid metabolism and Cancer, Lipidomics of Cancer, Bioactive Lipids and Cancer, Nanotechnology for the Treatment of Diseases, Targeting Lipid Metabolism

CONVENORS

  • Dr Jorge Gutierrez LE STUDIUM RESEARCH FELLOW
    In Résidence at INSERM / University François-Rabelais of Tours
    Centre Hospitalier Universitaire de Tours
    Inserm U1069 - Équipe Nutrition, Croissance et Cancer x et Nanostructures / Cell Biology, Cancer Research, Physiology
  • Dr Philippe Frank 
    Inserm U1069 - Équipe Nutrition, Croissance et Cancer x et Nanostructures / Cell Biology, Cancer Research, Physiology

CONFIRMED Invited speakers / TOPICS & TITLES

Nutrition and cancer
  • Pr Philip Calder, University of Southampton, UK
  • Dr Sébastien Roger, University François Rabelais of Tours, France
  • Dr Raffaella Gadaleta, Istituto Oncologico Giovanni Paolo II, Bari, Italy
Lipid metabolism and Cellular Signaling
  • Pr Johannes Swinnen, University of Leuven, Belgium
  • Pr William Griffiths, Swansea University, UK
  • Dr Lucie Brisson, University François Rabelais of Tours, France
  • Pr Gabriella Calviello, Institute of General Pathology, School of Medicine, Catholic University, Rome, Italy
Bioactive Lipids and Cancer (LXR, PPAR…)
  • Dr Marc Poirot, Université de Toulouse, Toulouse, France
  • Dr Silvère Baron, Clermont University, France
  • Dr Ana Maria Bouchet, University François Rabelais of Tours, France
  • Pr Faustino Mollinedo, Department of Cellular and Molecular Medicine,Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Biológicas (CSIC), Madrid, Spain 
Nanotechnology for the treatment of cancer - Targeting Lipid Metabolism

PROGRAMME

October 10, 2016

  • 12H00    Registration/Welcome lunch/ Poster installation
  • 13H30    Official opening
  • 13H40    Acknowledgement 
  • 13H50    Scientific opening 
Nutrition and cancer
  • 14H00    Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
    Raffaella Gadaleta, Istituto Oncologico Giovanni Paolo II, Bari, Italy
  • 14H45    Omega-3 fatty acids and inflammation: relevance to cancer.
    Philip Calder, University of Southampton, UK 
  • 15H30    Break/Poster discussions
  • 16H20    Docosahexaenoic acid treatment, and suppression of PPARβ, inhibit NaV1.5 and NHE-1 pro-invasive activities in human breast cancer cells.
    Sébastien Roger, University François Rabelais of Tours, France
  • 18H30    Conference grand public: Les lipides et le risque de cancer du sein
    Pr Stephan Chevalier, Directeur de l’Unité Inserm-Université 1069 «Nutrition, croissance et Cancer»
  • 20H00    Wine and cheese

October 11, 2016

  • 08H30    Registration/Welcome coffee
Lipid metabolism and Cellular Signaling
  • 09H00    Effect of an ether-lipid derivate on the plasma membrane of metastatic cells.
    Ana Maria Bouchet, University François Rabelais of Tours, France 
  • 09H35    n-3 PUFA as potential adjuvants in combination with targeted anticancer therapies.
    Gabriella Calviello, Institute of General Pathology, School of Medicine, Catholic University, Rome, Italy.
  • 10H10    Break/Poster discussions
  • 10H50    Lipid metabolism as antineoplastic target and modulator of cancer therapy response.
    Johan Swinnen, University of Leuven, Belgium
  • 11H35    Unravelling new pathways of sterol metabolism.
    William Griffiths, Swansea University, UK
  • 12H20    Lunch
Nanotechnology for the treatment of human diseases - Targeting Lipid Metabolism
  • 13H30    Development of synthetic HDL nanoparticles for the treatment of cardiovascular disease.
    Alan T. Remaley, Lipoprotein Metabolism Section, Pulmonary and Vascular Medicine Branch, NHLBI, NIH, Bethesda, Maryland
  • 14H15    Nanoparticles in cancer: Bimodal magneto-photo therapies & Impact of the intracellular environment.
    Claire Wilhelm, Université Paris 7 Diderot, Paris, France
  • 15H00    Break/Poster discussions
  • 15H30    Nano lipoparticles in cancer therapies:  lesson to be learned from CER-001, a pre-beta HDL mimetic currently in phase II and phase III clinical trials.
    Ronald Barbaras, Cerenis therapeutics, Toulouse, France
  • 16H30    Bus to Villandry
  • 20H00    Gala Dinner

October 12, 2016

  • 08H30    Morning coffee
Bioactive Lipids and Cancer (LXR, PPAR…)
  • 09H00    Lactate dehydrogenase B controls lysosome activity and autophagy in cancer.
    Lucie Brisson, University François Rabelais of Tours, France
  • 09H35    Targeting LXR in prostate cancer: Good idea or bad trip?
    Silvère Baron, Clermont Université, France
  • 10H10    Break/Poster discussions
  • 10H40    Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the ether phospholipid edelfosine.
    Faustino Mollinedo, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain
  • 11H25    Cholesterol and its metabolites in the breast: carcinogenic or tumor suppressor?
    Marc Poirot, Université de Toulouse, Toulouse, France
  • 12H10    Conclusions
  • 12H20    Lunch

TALK, ABSTRACT & POSTER SUBMISSION

Abstract, Bio & Poster must be written in English. 

Poster

Please send your poster before the 3/10/2016 so that it can be included on the USB flash drive. Please note that we do not print the posters, but racks & pins will be provided for up to A0 sizes.

Talk

If you are interested in giving a talk, thank you for uploading your abstract during your registration. The number of talks is limited, convenors willl process a selection and confirm your presentation. 20min talk.

PRACTICAL INFORMATIONS

PRICING

Private institutions 250 EUR
Researchers 180 EUR
Students 75 EUR
Gala dinner 60 EUR

 

SCIENTIFIC COMMITTEE

  • Dr Philippe Frank, Inserm U1069 - Équipe Nutrition, Croissance et Cancer et Nanostructures / Cell Biology, Cancer Research, Physiology
  • Pr Stephan Chevalier, Inserm U1069 - Équipe Nutrition, Croissance et Cancer (N2C)
  • Dr Jorge Gutierrez LE STUDIUM RESEARCH FELLOW, Inserm U1069 - Équipe Nutrition, Croissance et Cancer x et Nanostructures / Cell Biology, Cancer Research, Physiology

with the support of the Fondation ARC

Partners of the event

Lipids, Nanotechnology and Cancer